As long as current rebating and contracting practices continue, payers are part of the problem, not the solution, in promoting development of a vibrant biosimilars market, US FDA Commissioner Scott Gottlieb told America's Health Insurance Plans at their National Health Policy Conference in Washington, D.C. March 7.
In a speech on "Affording Tomorrow's Cures," Gottlieb steered clear of challenging high drug pricing and instead leveled strong criticism...